CHMP Opposes Lilly’s Mounjaro in Heart Failure, Backs Novo’s Kayshild

Why It Matters

Denial of Mounjaro stalls Lilly’s diversification into cardiology, whereas approval of Kayshild accelerates Novo’s revenue pipeline and could capture a share of the multi‑billion‑euro heart‑failure market.

Key Takeaways

• Mounjaro rejected for heart failure indication by CHMP
• Novo's Kayshild receives positive CHMP opinion
• Lilly's tirzepatide trial missed primary endpoint
• Kayshild showed 15% reduction in CV events
• EU market potential exceeds €5 billion annually

Pulse Analysis

The CHMP’s latest opinions underscore the EU’s rigorous stance on cardiovascular drug approvals. By demanding robust efficacy and safety data, the committee aims to protect patients while ensuring that only therapies with clear clinical benefit reach the market. This regulatory prudence is especially critical in heart failure, a condition where incremental improvements can translate into substantial survival gains. Consequently, the CHMP’s split decision—rejecting Lilly’s tirzepatide but endorsing Novo’s Kayshild—highlights how nuanced data packages can tip the balance between approval and denial.

For Eli Lilly, the setback represents a missed opportunity to leverage tirzepatide’s metabolic benefits in a high‑need cardiology niche. The drug’s weight‑loss success has driven strong sales, but extending its label to heart failure required convincing evidence of cardiovascular risk reduction, which the CHMP found lacking. Without EU approval, Lilly must rely on other regions or additional trials to salvage the indication, delaying potential revenue streams estimated in the billions. The decision also signals to investors that the company’s cardiology ambitions may face further regulatory hurdles, prompting a reassessment of its pipeline priorities.

Novo Nordisk, by contrast, gains a strategic foothold in the European heart‑failure market with Kayshild’s positive opinion. The Phase III data, showing a 15% cut in cardiovascular death or hospitalization, positions the drug alongside established SGLT2 inhibitors, expanding Novo’s therapeutic portfolio beyond diabetes. With the EU market valued at over €5 billion annually, Kayshild could become a significant revenue driver, especially as clinicians seek combination therapies for complex patients. The endorsement also bolsters Novo’s reputation for delivering high‑impact cardiovascular solutions, potentially accelerating uptake in other jurisdictions and shaping future research collaborations.